摘要
三阴性乳腺癌(triple-negative breast cancer,TNBC)作为乳腺癌的一个亚型,其复发率较高而总生存率低。尽管其对于包含蒽环类和紫衫类药物为基础的新辅助化疗方案反应显著,但预后较差。目前尚未发现专门的分子及化疗药物作用靶点。铂类并非是治疗三阴性乳腺癌的常规用药,本文对铂药物用于三阴性乳腺癌新辅助化疗的现状进行综述。
Triple -negative breast cancer（ TNBC）, as a subtype of breast cancer,associate with a higher recurrence rate and a low overall survival. It is associated with a dismal prognosis despite responding remarkably well to anthracy- cline and taxane - based neoadjuvant chemotherapy. No specific molecular targets or chemotherapeutic vulnerabilities have been identified. Platinum is a chemotherapeutic agent not used routinely for breast cancer treatment. This paper explored neoadjuvant chemotherapy of platinum in TNBCs.
出处
《现代肿瘤医学》
CAS
2015年第3期434-436,共3页
Journal of Modern Oncology
关键词
铂类
三阴性乳腺癌
新辅助化疗
platinum
triple negative breast cancer
neoadjuvant chemotherapy
